Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ANRO
#2470
Alto Neuroscience Inc.
19.5
8
+3.76%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+3.76%
Monthly Change
+19.32%
6 month change
+371.81%
Cambio anual
+596.80%
Cierres anteriores
18.8
7
Open
19.3
9
Bid
Ask
Low
19.2
4
High
19.6
8
Volumen
40
Markets
Acciones
Atención Sanitaria
ANRO
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Key stats
Total common shares outstanding
27.07 M
—
Valuation ratios
Enterprise value
-53.68 M
-256.91 M
Price to earnings ratio
-1.69
-5.35
Price to sales ratio
2 001.28
2 279.3
Price to cash flow ratio
-2.19
-6.22
Price to book ratio
0.69
1.07
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
0.35
0.38
Return on equity %
0.41
0.48
Return on invested capital %
3 344.79
3 119.1
Gross margin %
100
400
Operating margin %
131.94 K
1.94 M
EBITDA margin %
—
—
Net margin %
118.14 K
1.84 M
Liquidity ratios
Quick ratio
—
—
Current ratio
16.92
73.3
Inventory turnover
—
—
Asset turnover
0
0.01
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.06
0.44
Long term debt to total equity ratio
0.07
0.56
Per share metrics
Operating cash flow per share
1.93
2.02
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
6.84
23.32
Net current asset value per share
6.88
23.61
Tangible book value per share
6.16
19.97
Working capital per share
6.48
22.3
Book value per share
6.16
19.97
Noticias
Alto Neuroscience completa inscripción en ensayo de fármaco para esquizofrenia
Alto Neuroscience completa la inscripción en ensayo de fármaco para esquizofrenia
Alto Neuroscience completes enrollment in schizophrenia drug trial
Alto Neuroscience recibe patente para método de tratamiento de depresión
Alto Neuroscience recibe patente para método de tratamiento de depresión
Alto Neuroscience receives patent for depression treatment method
Chardan Capital Markets asume cobertura de Alto Neuroscience con calificación de Compra
Chardan Capital Markets inicia cobertura de Alto Neuroscience con calificación de Compra
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating
Tesla and ServiceNow among market cap stock movers on Monday
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 (NYSE:ANRO)
Google, Alibaba among market cap stock movers on Monday